A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

NCT07298330 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis D Infection

Interventions

DRUG: Brelovitug 300 mg
DRUG: Brelovitug 900 mg
DRUG: Delayed Treatment with Brelovitug 300mg

Sponsor

Mirum Pharmaceuticals, Inc.